glycine has been researched along with Inflammatory Response Syndrome, Systemic in 22 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sivelestat, a neutrophil elastase inhibitor, has been approved in Japan for the treatment of patients with acute lung injury (ALI) associated with systemic inflammatory response syndrome (SIRS)." | 9.15 | Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study. ( Aikawa, N; Endo, S; Hirasawa, H; Ikeda, T; Ishizaka, A; Kawasaki, Y; Shimazaki, S; Shinozaki, M; Sugimoto, H; Taenaka, N; Yamamoto, Y, 2011) |
| "48 Sprague-Dawley (SD) rats were divided into 3 groups: normal control group, severe burns injury group and severe burns treated with sivelestat sodium hydrate group (SSI)." | 7.83 | Sivelestat sodium hydrate attenuates acute lung injury by decreasing systemic inflammation in a rat model of severe burns. ( Huang, P; Li, QG; Xiao, XG; Zu, HG, 2016) |
| "Sivelestat sodium hydrate (sivelestat) is a specific neutrophil elastase inhibitor that is effective in treating acute lung injury associated with systemic inflammatory response syndrome." | 7.80 | Sivelestat sodium hydrate inhibits neutrophil migration to the vessel wall and suppresses hepatic ischemia-reperfusion injury. ( Fujimura, T; Fushida, S; Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Munesue, S; Nakagawara, H; Nakanuma, S; Ohta, T; Saito, H; Sakai, S; Tajima, H; Yamamoto, Y, 2014) |
| " We investigated the patients' background, pneumonia severity score, the days from diagnosis of systemic inflammatory response syndrome (SIRS) to sivelestat administration, P/F ratio, SIRS score, and compared two groups: those who survived and those who died." | 7.74 | [Efficacy of sivelestat for acute lung injury due to severe bacterial pneumonia with systemic inflammatory response syndrome]. ( Izumikawa, K; Kakeya, H; Kohno, S; Mukae, H; Nakamura, S; Seki, M; Tashiro, T; Yamamoto, Y; Yanagihara, K, 2008) |
| "To conduct a cost-minimisation analysis of sivelestat sodium hydrate treatment for patients in the intensive care unit (ICU) with acute lung injury (ALI) associated with systemic inflammatory response syndrome (SIRS) caused by infection." | 7.73 | Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome. ( Abiru, T; Aikawa, N; Fujishima, S; Kobayashi, M; Matsuoka, S, 2005) |
| "We assessed the effects of a neutrophil elastase inhibitor, sivelestat, on respiratory and organ functions as well as on the mortality of patients with acute respiratory distress syndrome (ARDS) associated with systemic inflammatory response syndrome (SIRS)." | 7.73 | Clinical effects of a neutrophil elastase inhibitor, sivelestat, in patients with acute respiratory distress syndrome. ( Imabayashi, T; Kakihana, Y; Kanmura, Y; Matsunaga, A; Okayama, N; Omae, T; Setoguchi, D, 2006) |
| " Sivelestat has been used clinically to treat acute lung injury associated with systemic inflammatory response syndrome." | 5.17 | Neutrophil elastase inhibitor sivelestat attenuates perioperative inflammatory response in pediatric heart surgery with cardiopulmonary bypass. ( Inoue, N; Itatani, K; Kitamura, T; Miyaji, K; Oka, N; Shibata, K; Tomoyasu, T, 2013) |
| "Sivelestat, a neutrophil elastase inhibitor, has been approved in Japan for the treatment of patients with acute lung injury (ALI) associated with systemic inflammatory response syndrome (SIRS)." | 5.15 | Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study. ( Aikawa, N; Endo, S; Hirasawa, H; Ikeda, T; Ishizaka, A; Kawasaki, Y; Shimazaki, S; Shinozaki, M; Sugimoto, H; Taenaka, N; Yamamoto, Y, 2011) |
| "48 Sprague-Dawley (SD) rats were divided into 3 groups: normal control group, severe burns injury group and severe burns treated with sivelestat sodium hydrate group (SSI)." | 3.83 | Sivelestat sodium hydrate attenuates acute lung injury by decreasing systemic inflammation in a rat model of severe burns. ( Huang, P; Li, QG; Xiao, XG; Zu, HG, 2016) |
| "Sivelestat sodium hydrate (sivelestat) is a specific neutrophil elastase inhibitor that is effective in treating acute lung injury associated with systemic inflammatory response syndrome." | 3.80 | Sivelestat sodium hydrate inhibits neutrophil migration to the vessel wall and suppresses hepatic ischemia-reperfusion injury. ( Fujimura, T; Fushida, S; Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Munesue, S; Nakagawara, H; Nakanuma, S; Ohta, T; Saito, H; Sakai, S; Tajima, H; Yamamoto, Y, 2014) |
| "Sivelestat, a selective inhibitor of neutrophil elastase, has been reported to reduce acute lung injury associated with systemic inflammatory response syndrome." | 3.79 | Preventive effect of sivelestat on postoperative respiratory disorders after thoracic esophagectomy. ( Baba, H; Baba, Y; Hirashima, K; Iwatsuki, M; Karashima, R; Kinoshita, K; Kurashige, J; Nagai, Y; Watanabe, M, 2013) |
| " We investigated the patients' background, pneumonia severity score, the days from diagnosis of systemic inflammatory response syndrome (SIRS) to sivelestat administration, P/F ratio, SIRS score, and compared two groups: those who survived and those who died." | 3.74 | [Efficacy of sivelestat for acute lung injury due to severe bacterial pneumonia with systemic inflammatory response syndrome]. ( Izumikawa, K; Kakeya, H; Kohno, S; Mukae, H; Nakamura, S; Seki, M; Tashiro, T; Yamamoto, Y; Yanagihara, K, 2008) |
| "To conduct a cost-minimisation analysis of sivelestat sodium hydrate treatment for patients in the intensive care unit (ICU) with acute lung injury (ALI) associated with systemic inflammatory response syndrome (SIRS) caused by infection." | 3.73 | Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome. ( Abiru, T; Aikawa, N; Fujishima, S; Kobayashi, M; Matsuoka, S, 2005) |
| "We assessed the effects of a neutrophil elastase inhibitor, sivelestat, on respiratory and organ functions as well as on the mortality of patients with acute respiratory distress syndrome (ARDS) associated with systemic inflammatory response syndrome (SIRS)." | 3.73 | Clinical effects of a neutrophil elastase inhibitor, sivelestat, in patients with acute respiratory distress syndrome. ( Imabayashi, T; Kakihana, Y; Kanmura, Y; Matsunaga, A; Okayama, N; Omae, T; Setoguchi, D, 2006) |
| "Sivelestat sodium was administered within 24 h after the onset of respiratory dysfunction in 87." | 1.36 | A survey of the effects of sivelestat sodium administration on patients with postoperative respiratory dysfunction. ( Harada, N; Harimoto, N; Kakeji, Y; Koga, T; Maehara, Y; Miyazaki, M; Morita, M; Nagata, S; Oki, E; Saeki, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (59.09) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagai, Y | 1 |
| Watanabe, M | 1 |
| Baba, Y | 1 |
| Iwatsuki, M | 1 |
| Hirashima, K | 1 |
| Karashima, R | 1 |
| Kurashige, J | 1 |
| Kinoshita, K | 1 |
| Baba, H | 1 |
| Aikawa, N | 3 |
| Inoue, N | 1 |
| Oka, N | 1 |
| Kitamura, T | 1 |
| Shibata, K | 1 |
| Itatani, K | 1 |
| Tomoyasu, T | 1 |
| Miyaji, K | 1 |
| Sakai, S | 1 |
| Tajima, H | 1 |
| Miyashita, T | 1 |
| Nakanuma, S | 1 |
| Makino, I | 1 |
| Hayashi, H | 1 |
| Nakagawara, H | 1 |
| Kitagawa, H | 1 |
| Fushida, S | 1 |
| Fujimura, T | 1 |
| Saito, H | 1 |
| Munesue, S | 1 |
| Yamamoto, Y | 3 |
| Ohta, T | 1 |
| Xiao, XG | 1 |
| Zu, HG | 1 |
| Li, QG | 1 |
| Huang, P | 1 |
| Nakamura, S | 1 |
| Yanagihara, K | 1 |
| Izumikawa, K | 1 |
| Seki, M | 1 |
| Kakeya, H | 1 |
| Mukae, H | 1 |
| Tashiro, T | 1 |
| Kohno, S | 1 |
| Saeki, H | 1 |
| Morita, M | 1 |
| Harada, N | 1 |
| Harimoto, N | 1 |
| Nagata, S | 1 |
| Miyazaki, M | 1 |
| Koga, T | 1 |
| Oki, E | 1 |
| Kakeji, Y | 1 |
| Maehara, Y | 1 |
| Ishizaka, A | 1 |
| Hirasawa, H | 1 |
| Shimazaki, S | 1 |
| Sugimoto, H | 2 |
| Shinozaki, M | 1 |
| Taenaka, N | 1 |
| Endo, S | 2 |
| Ikeda, T | 1 |
| Kawasaki, Y | 1 |
| Yamaguchi, K | 1 |
| Sugasawa, Y | 1 |
| Takeuchi, K | 1 |
| Kugimiya, T | 1 |
| Kumakura, S | 1 |
| Iwanuma, Y | 1 |
| Kajiyama, Y | 1 |
| Tsurumaru, M | 1 |
| Nagaoka, I | 1 |
| Inada, E | 1 |
| Iwata, K | 1 |
| Kawabata, K | 1 |
| Hagio, T | 1 |
| Matsuoka, S | 2 |
| Bellomo, R | 1 |
| Uchino, S | 1 |
| Naka, T | 1 |
| Wan, L | 1 |
| Sutherland, AM | 1 |
| Walley, KR | 1 |
| Manocha, S | 1 |
| Russell, JA | 1 |
| Fujishima, S | 1 |
| Kobayashi, M | 1 |
| Abiru, T | 1 |
| Okayama, N | 1 |
| Kakihana, Y | 1 |
| Setoguchi, D | 1 |
| Imabayashi, T | 1 |
| Omae, T | 1 |
| Matsunaga, A | 1 |
| Kanmura, Y | 1 |
| Ryugo, M | 1 |
| Sawa, Y | 1 |
| Takano, H | 1 |
| Matsumiya, G | 1 |
| Iwai, S | 1 |
| Ono, M | 1 |
| Hata, H | 1 |
| Yamauchi, T | 1 |
| Nishimura, M | 1 |
| Fujino, Y | 1 |
| Matsuda, H | 1 |
| Inoue, Y | 2 |
| Tanaka, H | 1 |
| Ogura, H | 1 |
| Ukai, I | 1 |
| Fujita, K | 1 |
| Hosotsubo, H | 1 |
| Shimazu, T | 1 |
| Minami, T | 1 |
| Kito, K | 1 |
| Utsugi, M | 1 |
| Ishizuka, T | 1 |
| Hisada, T | 1 |
| Shimizu, Y | 1 |
| Dobashi, K | 1 |
| Mori, M | 1 |
| Kodama, T | 1 |
| Yukioka, H | 1 |
| Kato, T | 1 |
| Kato, N | 1 |
| Hato, F | 1 |
| Kitagawa, S | 1 |
| Giger, U | 1 |
| Büchler, M | 1 |
| Farhadi, J | 1 |
| Berger, D | 1 |
| Hüsler, J | 1 |
| Schneider, H | 1 |
| Krähenbühl, S | 1 |
| Krähenbühl, L | 1 |
| Sato, N | 1 |
| Yaegashi, Y | 1 |
| Suzuki, Y | 1 |
| Kojika, M | 1 |
| Yamada, Y | 1 |
| Yoshida, Y | 1 |
| Nakadate, T | 1 |
| Aoki, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Perioperative Application of Sivelestat Sodium in Acute Type A Aortic Dissection Patients With Preoperative Moderate to Severe Hypoxemia to Shorten the Duration of Postoperative Invasive Mechanical Ventilation[NCT05874700] | 30 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy[NCT02655081] | Phase 2 | 48 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for glycine and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
[Pharmacological profile of a specific neutrophil elastase inhibitor, Sivelestat sodium hydrate].
Topics: Animals; Clinical Trials, Phase III as Topic; Disease Models, Animal; Glycine; Humans; Leukocyte Ela | 2003 |
8 trials available for glycine and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Neutrophil elastase inhibitor sivelestat attenuates perioperative inflammatory response in pediatric heart surgery with cardiopulmonary bypass.
Topics: Cardiac Surgical Procedures; Cardiopulmonary Bypass; Double-Blind Method; Female; Glycine; Humans; I | 2013 |
Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study.
Topics: Acute Lung Injury; Aged; Aged, 80 and over; Female; Glycine; Humans; Infusions, Intravenous; Male; M | 2011 |
Effects of sivelestat on bronchial inflammatory responses after esophagectomy.
Topics: Acute Lung Injury; Aged; Bronchitis; Esophagectomy; Female; Glycine; Humans; Interleukin-6; Interleu | 2011 |
Effect of a polymorphonuclear elastase inhibitor (sivelestat sodium) on acute lung injury after cardiopulmonary bypass: findings of a double-blind randomized study.
Topics: Acute Disease; Aged; Cardiopulmonary Bypass; Female; Glycine; Humans; Interleukin-8; Leukocyte Elast | 2006 |
A neutrophil elastase inhibitor, sivelestat, improves leukocyte deformability in patients with acute lung injury.
Topics: Adult; Aged; APACHE; C-Reactive Protein; Cell Membrane; Elasticity; Female; Glycine; Humans; Leukocy | 2006 |
Neutrophil elastase as a predicting factor for development of acute lung injury.
Topics: Adult; Aged; Aged, 80 and over; Female; Glycine; Humans; Leukocyte Elastase; Male; Middle Aged; Pred | 2007 |
Preoperative immunonutrition suppresses perioperative inflammatory response in patients with major abdominal surgery-a randomized controlled pilot study.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; C-Reactive Protein; Enteral | 2007 |
Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction.
Topics: Acute Disease; Adolescent; Adult; Aged; Glycine; Humans; Interleukin-8; Leukocyte Elastase; Leukocyt | 2006 |
13 other studies available for glycine and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Preventive effect of sivelestat on postoperative respiratory disorders after thoracic esophagectomy.
Topics: Acute Lung Injury; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Drug Administration Sch | 2013 |
The propensity score analysis on the efficacy of Sivelestat - author's reply.
Topics: Acute Lung Injury; Female; Glycine; Humans; Male; Serine Proteinase Inhibitors; Sulfonamides; System | 2013 |
Sivelestat sodium hydrate inhibits neutrophil migration to the vessel wall and suppresses hepatic ischemia-reperfusion injury.
Topics: Animals; Cell Adhesion; Chemotaxis, Leukocyte; Disease Models, Animal; Dose-Response Relationship, D | 2014 |
Sivelestat sodium hydrate attenuates acute lung injury by decreasing systemic inflammation in a rat model of severe burns.
Topics: Acute Lung Injury; Animals; Blood Gas Analysis; Burns; Disease Models, Animal; Glycine; Inflammation | 2016 |
[Efficacy of sivelestat for acute lung injury due to severe bacterial pneumonia with systemic inflammatory response syndrome].
Topics: Acute Lung Injury; Aged; Aged, 80 and over; Female; Glycine; Humans; Leukocyte Elastase; Male; Pneum | 2008 |
A survey of the effects of sivelestat sodium administration on patients with postoperative respiratory dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Female; Glycine; Health Status; Health Surveys; Humans; Inflammation | 2010 |
The propensity score analysis on the efficacy of sivelestat.
Topics: Acute Lung Injury; Female; Glycine; Humans; Male; Serine Proteinase Inhibitors; Sulfonamides; System | 2013 |
Hidden evidence to the West: multicentre, randomised, controlled trials in sepsis and systemic inflammatory response syndrome in Japanese journals.
Topics: Anti-Inflammatory Agents; Communication Barriers; Double-Blind Method; Evidence-Based Medicine; Glyc | 2004 |
The association of interleukin 6 haplotype clades with mortality in critically ill adults.
Topics: Adult; Aged; Cohort Studies; Critical Illness; Cysteine; Female; Gene Frequency; Genotype; Glycine; | 2005 |
Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cost Savings; Female; Glycine; Health Care Costs; Humans | 2005 |
Clinical effects of a neutrophil elastase inhibitor, sivelestat, in patients with acute respiratory distress syndrome.
Topics: Aged; Female; Glycine; Humans; Leukocyte Elastase; Male; Middle Aged; Respiratory Distress Syndrome; | 2006 |
[Prophylactic effects of neutrophil elastase inhibitor for patients undergoing surgery for thoracic aortic aneurysm: a retrospective study].
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Thoracic; Cardiopulmonary Bypass; Female; Glycine; Humans; | 2006 |
Acute respiratory failure associated with miliary tuberculosis successfully treated with sivelestat sodium hydrate.
Topics: Antitubercular Agents; Glycine; Humans; Male; Middle Aged; Respiratory Distress Syndrome; Serine Pro | 2006 |